$PRLD

Analysts made several calls on Thursday. Goldman upgraded Sunbelt citing growth improvement. Wolfe reiterated Tesla as peer perform. Bernstein downgraded Palo Alto Networks, Okta, and SentinelOne due to valuation. Citizens upgraded JBHT to market outperform. Daiwa reiterated Nvidia as outperform but lowered its price target to $245. RBC initiated Kraft Heinz as outperform. Wells Fargo initiated several bitcoin miners as overweight. Barclays reinstated Paramount Skydance as underweight and Warner

Prelude Therapeutics (PRLD) received FDA clearance for its IND application for PRT13722, a KAT6A selective degrader, to treat HR+/HER2- breast cancer. The company plans to start a Phase 1 trial in Q4 2026. PRT13722 aims to improve efficacy and safety over existing therapies. PRLD's stock closed at $5.09, down 3.96%, and was at $5.10 in pre-market trading.

Several biotech stocks hit 52-week highs on August 21, 2026. Eloxx (ELOX) rose 16% to $23.40, reporting a Q2 net loss of $4.5M. argenX (ARGX) reached $1,058.69, with positive trial results for VYVGART. Corcept (CORT) hit $123.44, reporting $256M in Q2 revenue. Boundless Bio (BOLD) reached $3.02, initiating a first-in-human trial. Prelude (PRLD) peaked at $6.38, advancing JAK2V617F in Phase 1 trials.

Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.

Prelude Therapeutics (PRLD) reported Q2 2026 revenue of $5.7M and a net loss of $13.9M, or $0.14 per share. The company said it had $155.2M in cash and marketable securities as of June 30, 2026, projecting a runway into Q2 2028. R&D and G&A fell year over year. It also updated Phase 1 timelines for PRT13722 and PRT12396.

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

Prelude Therapeutics Inc (PRLD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001678660 false 0001678660 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2

HC Wainwright & Co. analyst Robert Burns maintained a 'Buy' rating for Prelude Therapeutics (PRLD) and raised the price target to $8 from $5, a 60% increase. The positive outlook is based on the company's innovative pipeline in oncology. Despite a low GF Score™ of 37/100, indicating financial challenges, insider buying of $25.0 million in the past three months suggests confidence in the company's future.

Prelude Therapeutics announced preclinical data for PRT13722, a first-in-class, orally bioavailable KAT6A degrader for HR+/HER2- breast cancer. The data show potential for differentiated efficacy and safety, including complete responses as monotherapy in various models. Prelude aims to file an Investigational New Drug (IND) application by mid-2026 and initiate a clinical trial in the second half of 2026.